Objectives Cold-induced vasoconstriction is mediated in part by selective enhancement of local a 2C -adrenoceptor (a 2C -AR) activity. A common insertion-deletion variant in the a 2C -AR gene (ADRA2C del322-325) results in an approximately 85% reduction of agonist-mediated function in vitro. We tested the hypothesis that individuals with the ADRA2C del322-325 variant have attenuated vasoconstriction in response to cold. Methods Cutaneous digital blood flow (flux) was measured by laser Doppler flowmetry in a controlled environment at room temperature and during two cycles of graduated local heat and cold exposure in 31 subjects. Temperature-response curves were analyzed to estimate the following measures: E min (minimal flux during cooling), and ET 50 and ET 90 (the local temperature at which flux decreased by 50 and 90%, respectively). Results We found no significant genotypic differences in E min (24.3 ± 19.5, 30.0 ± 20.5, and 21.5 ± 25.9 AU for ins/ins, ins/del, and del/del genotypes, respectively; P = 0.48), ET 50 (25.5 ± 6.0, 25.1 ± 6.7, and 25.1 ± 7.1°C; P = 0.99), or ET 90 (20.5 ± 4.7, 22.1 ± 4.0, and 20.8 ± 6.7°C; P = 0.77) in either the first or second heating and cooling cycle (cycle 1 values presented).
Introduction
Cold-induced vasoconstriction of peripheral blood vessels serves as a physiologic reflex to conserve central body heat during cold exposure. This occurs via a reflex increase in sympathetic activity coupled with local alterations, resulting in increased vascular sensitivity to norepinephrine [8, 11] . Vasoconstriction in response to cold is mediated by the rapid selective enhancement of local a 2 -adrenergic receptor (a 2 -AR) activity [12, 19] and is inhibited by an a 2 -AR antagonist [9] . Excessive cold-induced vasoconstriction is the hallmark of Raynaud's phenomenon, a clinical disorder that affects between 8 and 11% of the general population [34] , and Raynaud's phenomenon has been linked to a 2 -AR dysfunction [14, 15] .
There are three subtypes of a 2 -ARs: a 2A , a 2B , and a 2C [4, 28] . At 37°C, a 2 -AR-mediated vasoconstriction is conveyed primarily by the a 2A subtype [8] , and the a 2C -AR has minimal activity, as it is not expressed at the cell surface, but sequestered predominantly in the Golgi apparatus [19] . Hence, the a 2C -AR was originally thought to be a ''silent receptor'' [8] . However, cooling activates rho-kinase signaling [1] and evokes a redistribution of a 2C -ARs to the cell surface, enhancing vasoconstrictor responses to norepinephrine [19] and mediating vasoconstriction in response to cold. Furthermore, selective inhibition of the a 2C -AR attenuates the increased sensitivity to adrenergic agonists during cold exposure [8] . Thus, the a 2C -AR is a key mediator of vasoconstriction in response to cold and, therefore, has become a drug target for the development of subtype selective antagonists. Indeed, pharmacological treatment with such an investigational selective a 2C -AR antagonist has been explored as a potential therapy for Raynaud's phenomenon [37] .
A common genetic variant in the human a 2C -AR gene (ADRA2C) results in the deletion of four amino acids, del322-325 [30] . The frequency of the deletion allele is 42.5 and 6.3% in African-Americans and Caucasians, respectively [32] , and it results in a reduction of approximately 85% of agonist-mediated function in vitro [30, 31] . In view of the a 2C -AR's key role in cold-induced vasoconstriction, the decreased function of the receptor encoded by the del322-325 variant may result in attenuation of cold-induced vasoconstriction. However, to date, the effects of this variant on vascular sensitivity to cold have not been defined.
We previously developed a method to measure changes in skin blood flow in response to controlled incremental local cold exposure [16] , and we used it in the present study to examine the hypothesis that subjects with the ADRA2C del322-325 variant have decreased vascular sensitivity to cooling. Since exposure to cold is required for a 2C -ARs to translocate to the cell surface and become active, we performed a second cold exposure test by repeating the heating/cooling cycle to examine whether previous cold exposure would change subsequent skin flux responses to cold.
Methods

Subjects
The study was approved by the Vanderbilt University Institutional Review Board, and all subjects provided written informed consent. To enrich the study population for the genotype of interest, we studied 31 AfricanAmerican subjects, since the ADRA2C del322-325 variant is rare in Caucasians. Unrelated males and females were eligible to participate if they were African-American, between 18 and 40 years of age, nonsmokers, and had no clinically significant abnormality based on medical history and physical examination. No laboratory screening was performed for this study, though for 29 of the 31 subjects, red blood cell (RBC) count values were available from previous recent studies, and these are included in Table 1 . Ethnicity was determined by self-report. Subjects were free of medications for at least 2 weeks. Since cutaneous blood flow varies with the menstrual cycle [6] , all women were studied in the luteal phase of the menstrual cycle.
Protocol
Subjects were admitted to the General Clinical Research Center of the Vanderbilt University Medical School at 8:00 a.m. on the morning of the study day after an overnight fast. All studies were performed in a temperature-controlled room (24.0 ± 1.0°C). After 30 min of acclimatization, a 20-G intravenous cannula was inserted into an antecubital arm vein for blood sampling. After an additional 30 min of supine comfortable rest, resting blood pressure and heart rate were obtained by a semi-automated device (Dinamap MPS; GE Medical Systems, Waukesha, WI, USA), and a venous blood sample (12 ml) was drawn from the uncuffed arm for the determination of plasma norepinephrine concentration.
The subject's contralateral hand was then inserted to a fixed location inside a thermally inert plexi-glass box. Laser probes (DP1T-V2, Moor Instruments, Devon, UK) were attached to the pulp of the distal phalanges of the third and fourth digits. Skin blood flow was assessed by laser Doppler flowmetry (DRT4, Moor Instruments, Devon, UK), and skin temperature by a thermocouple. The laser Doppler flowmeter produces an output signal based on the reflection of light off moving RBCs. This signal is proportional to the microvascular blood flow (flux), a Values represent mean ± standard deviation product of the number of RBCs in the sampling volume and the mean velocity [3] . Laser Doppler flux is proportional to blood flow, though the absolute value of the arbitrary units depends on many factors. There is considerable inter-individual variability in flux measurements; therefore, the greatest utility of laser Doppler lies in assessing relative within-subject changes in flow, rather than absolute flux differences between subjects [3] . Skin flux and skin temperature were recorded continuously on an attached computer. The box temperature was controlled by a modified heating and air conditioning unit (Whirlpool ACE082XR). A metal baffle placed before the airflow inlet ensured even temperature distribution within the box, as confirmed in preliminary studies [16] .
After an acclimatization period of at least 60 min, baseline skin flux and temperature measurements were recorded at room temperature for 10 min. The temperature in the box enclosing the hand was then increased gradually to 40.5°C within 5 min and maintained at that temperature for 20 min ( Fig. 1 ) [16] . During the following 60 min, the temperature in the box was decreased stepwise at 2-min intervals in approximately 2.5°C decrements to a minimum temperature of 8°C. We then performed a second cold exposure test by repeating the heating/cooling cycle to examine whether previous cold exposure would change subsequent skin flux responses to cold (Fig. 1) . During each cooling cycle, if skin flux did not change over three stepwise temperature decrements, this value was considered to represent maximum vasoconstriction in response to cold, and the cooling cycle was ended.
Blood samples (12 ml each) were drawn, and blood pressure was measured after 20 min at 40.5°C during the two heating cycles, and at the minimum temperature during the two cooling cycles.
Catecholamine determination
Blood was collected into cooled heparinized tubes, immediately placed on ice, and centrifuged at 4°C for 10 min at 3,000 rpm. Plasma was harvested and stored in tubes containing 40 ll of reduced glutathione (6%) at -20°C until assayed. Norepinephrine concentrations were measured by high-performance liquid chromatography using electrochemical detection with dihydroxybenzylamine as the internal standard [17] .
Preliminary studies
We performed a series of studies to optimize the heating/ cooling protocol and to assess reproducibility. Preliminary studies on within-subject reproducibility of ET 50 (n = 4) yielded a day-to-day difference of 1.6 ± 2.9°C.
Genotyping
After amplification of DNA fragments by polymerase chain reaction (PCR), ADRA2C del322-325 genotyping was performed by DNA fragment analysis as described previously [23] . In brief, a fluorescently labeled forward primer (5 0 -6-FAM-AGACGGACGAGAGCAGCGCA-3 0 ) and a reverse primer (5 0 -AGGCCTCGCGGCAGATGCCGTA CA-3 0 ) were used to amplify DNA fragments by PCR. Amplicons were denatured at 95°C for 5 min, and fragment analysis was performed on an ABI 3730 Genetic Analyzer and its Genotyper V.1.0.1 software. The success rate for genotyping was 100%. We use the term ''ADRA2C'' when referring to the gene and ''a 2C -AR'' when referring to the receptor encoded by the gene. Individuals homozygous for the ADRA2C insertion (wild type) allele, homozygous for the deletion allele, and heterozygous are termed ADRA2C ''ins/ins,'' ''del/del,'' or ''ins/del,'' respectively.
Data analysis and statistics
Skin temperature and skin blood flow (flux) were calculated as the average of the readings in the two fingers. Baseline skin temperature and flux were calculated as the average of values obtained over 10 min after subjects had been acclimated in the room for at least 60 min. For the heating/cooling cycles, for each subject, average flux during every 2 min temperature step was plotted against the box temperature, and nonlinear regression analysis was used to fit a sigmoidal curve (Prism v4.0, GraphPad Software Inc., San Diego, CA, USA; Fig. 2 ). The software provides estimates for the steady-state blood flow during the heating stimulation (E stim ), the minimum blood flow achieved during cooling (E min ), the box temperature at which flux decreased by half the maximal effect (ET 50 ), and the box temperature at which flux decreased by 90% (ET 90 ; Fig. 2 ). We interpreted E min to reflect maximal cold-induced vasoconstriction, and ET 50 and ET 90 to reflect the sensitivity to cooling. The software also calculates the R 2 value as a measure of goodness of curve fit. Skin temperature, which is determined by both ambient temperature and flux, was analyzed with the following parameters: T stim (the maximum skin temperature during heating stimulation), T min [the skin temperature at the time point of ET 90 , at which flux had decreased to 90% of the maximum change (E stim -E min )], and T mid (the skin temperature at the time when box temperature measured 24.5°C, a midpoint, approximately 71 min into the study).
Mean arterial blood pressure (MAP) was calculated as the diastolic blood pressure plus one-third of the systolic minus the diastolic pressure. All values are reported as mean ± standard deviation. A Kruskal-Wallis or Chisquare test was used to compare values in subjects with different ADRA2C genotypes. A repeated-measures analysis of variance (ANOVA) was used to compare plasma norepinephrine concentrations and mean arterial pressure readings, using ADRA2C genotype as a covariate. All tests were two-tailed, and a P value of \0.05 was considered significant. Analyses were performed with the statistical software SPSS (SPSS v14.0, SPSS Inc., Chicago, IL, USA).
Results
Subject characteristics
Demographic characteristics arranged by ADRA2C genotype are shown in Table 1 . There were no differences among subjects of different genotypes in any of the variables.
Skin flux and skin temperature measures
The mean (±SD) goodness-of-fit for the temperature-flux response curves, expressed as R 2 , was 0.89 ± 0.09. There were no significant differences in baseline skin blood flow (flux), E min , ET 50 , or ET 90 in either the first or second heating or cooling cycle between genotypes (Table 2) . Similarly, genotype was not associated with the skin Fig. 2 A representative curve of the relationship between box temperature and skin blood flow. The measurement parameters E stim (steady-state blood flow after heating), E min (minimal flux during cooling), and ET 50 (the box temperature at which flux decreased by 50% of the maximal change, E stim -E min ) are depicted temperature responses measured by T stim , T min , and T mid . The distributions of ET 50 and ET 90 for the first heating/ cooling cycle are shown in Fig. 3 . The stimulated flux during the first heating cycle (E stim ) was lower in the ADRA2C del/del genotype group than the ins/del and ins/ ins genotype groups (P = 0.01), but there was no difference in E stim during the second cycle (P = 0.64). There were no differences in the flux or skin temperature parameters between cycles 1 and 2.
Cardiovascular measures and plasma norepinephrine concentrations
Among subjects with different ADRA2C genotypes, there were no significant differences in MAP at baseline (Table 1 , P = 0.69) or during the course of the study (all P [ 0.21), and MAP did not change over time (P = 0.78). Similarly, plasma norepinephrine concentrations were not different at baseline (390.5 ± 258.4, 347.9 ± 165.3, and 327.0 ± 146.7 pg/dl, for ins/ins, ins/del, and del/del genotypes, respectively, P = 0.99), and the values did not change significantly during the study (P = 0.98).
Discussion
This is the first study to examine the effects of a common, functionally significant deletion polymorphism in the a 2C -adrenergic receptor on cold-induced vasoconstriction. Baseline skin blood flow and skin temperature were not associated with ADRA2C genotype, and neither the magnitude of vasoconstriction during cooling (E min ) nor the sensitivity of vasoconstriction to cold (ET 50 ) differed among ADRA2C genotypes.
Cold-induced vasoconstriction is an intricate physiologic defense mechanism that serves to reduce heat loss. Cooling induces vasoconstriction of arterioles via rapid augmentation of a 2 -AR activity. Both in vitro and in vivo studies have shown that inhibition of a 2 -ARs impairs the cold-induced vasoconstriction response [8, 9] . a 2C -ARs are located predominantly in small arteries, arterioles, and veins [10, 13, 24] and, although ''silent'' at 37°C, become the major effectors of vasoconstriction during cooling [11] . In response to cold, the a 2C -ARs translocate from the Golgi apparatus, where they are sequestered at physiologic temperature, to the cell surface, amplifying vasoconstriction in response to norepinephrine [19] . The response is likely further magnified by increased local sympathetic activation, resulting in greater norepinephrine release from the nerve terminal [21] . In vivo studies suggest that a 2 -AR upregulation is quite rapid and that a 2 -AR-mediated vasoconstriction can be seen as early as 1-5 min into cooling [7] . While the important role of a 2C -ARs in coldinduced vasoconstriction is well established, other mechanisms are also involved. For example, the production of reactive oxygen species in the smooth muscle cell mitochondria appears to function as a temperature sensing mechanism initiating the cascade [2] . Subsequently, rhokinase acts as a mediator whereby the a 2C -AR translocates to the plasma membrane [1, 35] . Recent studies have shown that both adrenergic and nonadrenergic mechanisms contribute to varying degrees, at different times, to the vascular response to cooling. The adrenergic mechanism, mediated by a 2C -AR, is responsible primarily for the early response to cooling (within the first 10 min). After prolonged cooling ([30 min), nonadrenergic mechanisms become more prominent [21, 38] . Adrenergic blockade does not prevent this late phase vasoconstriction. Inhibition of nitric oxide synthase appears to play a role in this late response, though the sympathetic cotransmitter neuropeptide Y [21] and endothelin [39] may potentially be involved.
The ADRA2C del322-325 variant results from the inframe deletion of 12 nucleotides in the coding region. The variant is located in the third intracellular loop of the a 2C -AR, in close proximity to the G i coupling domain. The deletion variant of the a 2C -AR exhibited impaired agonistreceptor-G protein coupling in transfected cells, resulting in approximately 85% loss of function [30] . Studies to elucidate the significance of this variant in man are limited.
One case-control study showed that African-American subjects who were homozygous for the ADRA2C del322-325 variant had an increased risk of heart failure, compared to heterozygotes and non-carriers [33] . In addition, a small controlled study in healthy subjects suggested that individuals' homozygous for the deletion variant had higher blood pressure and norepinephrine secretion [27] . However, more recent studies in larger cohorts did not show an association of the ADRA2C del322-325 variant with blood pressure and heart rate [23, 25] , more specific markers of resting sympathetic activity [23] , or early markers of congestive heart failure [5] . Despite the importance of the a 2C -AR in the vascular response to cold, there have been no studies to assess the effect of ADRA2C genetic variants on cold-induced vasoconstriction.
Given the finding that ADRA2C del322-325 leads to a marked loss of function in vitro, our hypothesis was that the ADRA2C variant del322-325 would be associated with a decreased vasoconstrictor response to local cooling. Our main outcome was the cooling response, assessed by the variables E min , ET 50 , and ET 90 , as well as T min and T mid . There were no differences in these variables in either cycle among genotype groups. During the first cycle, there was a trend to a lower baseline flux and a statistically significant lower stimulated flux (E stim ) in individuals with the homozygous deletion, findings that were not observed during the second cycle. These findings were of marginal significance and are likely to reflect incomplete acclimatization of skin flux responses to the experimental conditions. Moreover, there was no difference in the maximum skin temperature during cycle 1. In addition, as multiple factors lead to inter-individual variability in flux values, laser Doppler is most informative when assessing relative within-subject changes (such as ET 50 ) [3] .
We expected carriers of the deletion variant to show an attenuated vasoconstrictor response to cold. The study was sufficiently powered to detect physiologically important differences; the sample size provided 80% power with a = 0.05 to detect a 6 ± 5°C difference in ET 50 between subjects homozygous for the insertion allele and subjects with at least one deletion allele. Though non-adrenergic mechanisms contribute to the late cold-induced vasoconstriction response, in our study, we believe that in using the temperature-response curves and ET 50 measurements, we selected for adrenergic-dependent responses. The ET 50 of our temperature-response curves corresponded to a skin temperature typically in the range of 29-31°C, measured after approximately 10-15 min of gradual cooling. The contribution of a 2C -AR activity should have been near maximal during this time of our cooling protocol.
Possible explanations for the lack of effect of the ADRA2C del322-325 variant on cold-induced vasoconstriction could be functional redundancy in the vasoconstrictor and vasodilator systems [20] , opposing effects of pre-and postsynaptic hypofunctional a 2C -ARs on vasoconstriction, and that the a 2C -AR may be sufficient, but not necessary for cold-induced vasoconstriction in vivo. In addition, it is also possible that despite 85% reduced agonist-mediated function in vitro, residual activity of a 2C -AR del/del may be sufficient to effect in vivo cooling responses.
Compensatory variation in factors such as a 2A -ARs, rhokinase [29, 36] , or nitric oxide [18] , may mask any apparent loss of function associated with a 2C -AR variants. For example, the vasodilation in response to warming is in part related to nitric oxide release [22] . In our study, there was a trend toward decreased E stim flux in individuals with the ADRA2C del/del genotype ( Table 2 ). One could theorize that this lower plateau vasodilation reflects decreased nitric oxide production. If this decreased nitric oxide production carried forward into the cooling phase as well, this could mask effects of the ADRA2C deletion. In such a situation, the deletion variant a 2C -AR could still be hypofunctional, trending toward decreased vasoconstrictor activity, but if coupled with an attenuated nitric oxide response, this could shift the balance and restore vasoconstriction to ''normal'' levels.
Our study was designed to apply local heat and cold stimuli while avoiding extreme temperatures. Cutaneous blood flow is often low at room temperature. Therefore, after obtaining baseline measures, we applied a standardized local heat exposure to achieve vasodilation, reflected by an elevation in flux to steady state. For the heat stimulation, a box temperature of 40.5°C was selected, as this temperature has been shown to cause vasodilation, while higher temperatures may elicit nociceptive responses that increase skin blood flow via a mechanism independent of temperature itself [22, 26] . After heating, we gradually decreased the ambient temperature until flux reached a minimum. All temperatures in our testing sequence were within a range typically experienced in a temperate climate. The gradual cooling process allowed us to determine skin blood flow responses over the whole range of temperatures, such that we could accurately quantify the sensitivity of an individual's vasoconstrictor response to cold. We repeated the heating and cooling cycle to account for any residual baseline environmental effects present in the first cycle, as well as to assess whether upregulation of a 2C -AR-mediated signaling during cooling in the first cycle would affect responses during the second cooling cycle.
There are several limitations of our study. Our in vivo study design allowed us to examine local vascular responses and the effects of genetic variants within a physiologic system. A potential drawback to any in vivo study is that the effect of a genetic variant may be attenuated by local and systemic homeostatic and counter-regulatory systems. Central sympathetic nervous system activity, partially regulated by a 2C -ARs, could also affect peripheral vasoconstriction. Thus, we made an effort to avoid systemic responses triggered by heat or cold pain, and the lack of changes in MAP and plasma norepinephrine concentrations during the study indicates that systemic effects, if present, were minimal.
We believe that our parameters extrapolated from the temperature-response curves reflect adrenergic, a 2C -ARmediated mechanisms, since the ET 50 was measured at a temperature and time point at which cold-induced vasoconstriction has been shown to be most adrenergically mediated. However, validating this using an a 2 -AR antagonist could have been very informative. In addition, pharmacologic inhibition of nitric oxide production or rhokinase could have helped elucidate whether there were compensatory changes in these pathways masking effects of the ADRA2C del/del genotype.
In conclusion, in this study, the ADRA2C del322-325 variant did not affect vascular sensitivity to cold. Future exploration should involve in vitro studies to examine the effect of the deletion variant on cold-induced receptor translocation to the cell surface and in vivo studies using specific a 2C -AR antagonists. Moreover, the effect of genetic variants in associated proteins, e.g., rho-kinase, on cold-induced vasoconstriction will be of interest.
